Published in Eur Respir J on February 01, 2002
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med (2006) 3.16
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J (2012) 1.98
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax (2006) 1.76
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis (2012) 1.52
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res (2011) 1.51
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis (2010) 1.51
Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis (2014) 1.48
Chronic obstructive pulmonary disease . 7: Management of COPD. Thorax (2003) 1.47
Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis (2008) 1.46
Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ (2010) 1.41
A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J (2007) 1.40
Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.38
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med (2009) 1.37
Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis (2010) 1.35
Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol (2009) 1.33
Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis (2009) 1.32
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol (2011) 1.21
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax (2006) 1.18
Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax (2003) 1.16
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis (2007) 1.11
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res (2011) 1.09
Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. Respir Res (2007) 1.08
Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol (2011) 1.07
Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1alpha. Crit Care (2002) 1.07
Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med (2012) 1.04
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax (2005) 1.02
Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis (2008) 1.01
COPD symptoms in the morning: impact, evaluation and management. Respir Res (2013) 1.00
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.99
Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.99
Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.97
Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed (2006) 0.95
Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis (2014) 0.95
Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med (2010) 0.95
Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis (2007) 0.95
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.93
Impact of inhalation therapy on oral health. Lung India (2011) 0.92
Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis (2013) 0.92
The Saudi Guidelines for the Diagnosis and Management of COPD. Ann Thorac Med (2014) 0.92
Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation. Front Immunol (2014) 0.91
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis (2014) 0.91
Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.91
A bibliometric analysis of the 100 most influential papers on COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.90
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis (2013) 0.89
The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide study. PLoS One (2013) 0.89
Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.89
Pneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education. Multidiscip Respir Med (2014) 0.88
COPD exacerbations. 4: Prevention. Thorax (2006) 0.88
Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87
Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Int J Chron Obstruct Pulmon Dis (2015) 0.87
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis (2011) 0.87
Optimising treatment for COPD--new strategies for combination therapy. Int J Clin Pract (2009) 0.87
Pro-inflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir Res (2010) 0.87
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis (2009) 0.86
Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting? Drug Des Devel Ther (2013) 0.86
Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Proc (Bayl Univ Med Cent) (2004) 0.86
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol (2010) 0.86
Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis (2008) 0.86
Defining disease modification in chronic obstructive pulmonary disease. COPD (2009) 0.85
Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis (2009) 0.85
Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 0.84
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res (2010) 0.84
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.84
Management of an acute exacerbation of copd: are we ignoring the evidence? Thorax (2002) 0.83
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.83
Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. BMC Pulm Med (2014) 0.83
A cluster randomised controlled trial of nurse and GP partnership for care of chronic obstructive pulmonary disease. BMC Pulm Med (2008) 0.83
Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res (2016) 0.83
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities. Ther Adv Chronic Dis (2010) 0.83
Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Des Devel Ther (2015) 0.82
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J (2010) 0.82
Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2006) 0.82
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.82
The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes. Respir Res (2015) 0.82
Tiotropium bromide: an update. Open Respir Med J (2009) 0.82
The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respir Res (2016) 0.82
The development of anticholinergics in the management of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.81
Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease. Health Qual Life Outcomes (2011) 0.81
Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.81
Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease. Lung (2006) 0.80
Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.80
The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci (2007) 0.79
The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res (2009) 0.79
Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chron Obstruct Pulmon Dis (2008) 0.79
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Automated microbiological detection/identification system. J Clin Microbiol (1977) 16.88
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax (1999) 8.63
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Oxpentifylline treatment of venous ulcers of the leg. BMJ (1990) 3.75
Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax (2003) 3.62
Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax (2009) 3.54
Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J (2008) 3.36
Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J (2004) 2.80
Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med (1998) 2.56
Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 2.52
Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease. Thorax (1985) 2.47
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol (1998) 2.37
Mutation of invH, but not stn, reduces Salmonella-induced enteritis in cattle. Infect Immun (1998) 2.29
Cognitive function in COPD. Eur Respir J (2010) 2.22
Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med (1995) 2.20
Examination of slurry from cattle for pathogenic bacteria. J Hyg (Lond) (1975) 2.13
Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax (2003) 2.11
Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax (2003) 2.11
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J (2009) 2.11
The lactoperoxidase system functions in bacterial clearance of airways. Am J Respir Cell Mol Biol (2000) 2.08
Evidence for related virulence sequences in plasmids of Salmonella dublin and Salmonella typhimurium. J Gen Microbiol (1985) 2.07
A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) (1989) 2.06
Do routine antibiotics after loop diathermy excision reduce morbidity? Br J Obstet Gynaecol (1998) 2.05
Primary and revision lumbar discectomy. A 16-year review from one centre. J Bone Joint Surg Br (2003) 2.03
Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 2.01
Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med (1997) 2.01
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 1.98
Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax (2006) 1.96
American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther (2000) 1.90
Comparative Responses of Globodera rostochiensis and G. pallida to Hatching Chemicals. J Nematol (2001) 1.87
Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J (2003) 1.84
Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest (1996) 1.82
The Salmonella dublin virulence plasmid mediates systemic but not enteric phases of salmonellosis in cattle. Infect Immun (1995) 1.81
A randomised controlled trial of epidural compared with non-epidural analgesia in labour. BJOG (2001) 1.79
Characterization of intestinal invasion by Salmonella typhimurium and Salmonella dublin and effect of a mutation in the invH gene. Infect Immun (1995) 1.75
Identification of SopE2, a Salmonella secreted protein which is highly homologous to SopE and involved in bacterial invasion of epithelial cells. J Bacteriol (2000) 1.74
Current perspectives in salmonellosis. Br Vet J (1995) 1.72
Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) (2001) 1.70
Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax (1996) 1.69
The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med (2006) 1.67
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) (2000) 1.67
Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab (2010) 1.65
Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am J Respir Crit Care Med (2000) 1.61
Clinical aspects of mucociliary transport. Am Rev Respir Dis (1977) 1.61
Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett (2000) 1.59
A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.59
Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J (1998) 1.55
Dyspnea ratings for prescription of cross-modal exercise in patients with COPD. Chest (1998) 1.54
Microbiology of calf diarrhoea in southern Britain. Vet Rec (1986) 1.53
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.51
Adult coeliac disease, dermatitis herpetiformis and smoking. Gut (1997) 1.50
Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax (2009) 1.50
Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG (2002) 1.48
Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J (2011) 1.47
Salmonellosis in wild mammals. J Hyg (Lond) (1976) 1.46
Treatment of mucociliary dysfunction. Chest (1996) 1.45
Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. Clin Sci (Lond) (1990) 1.45
Accidents among children under five years old: a general practice based study in north Staffordshire. Br J Gen Pract (1993) 1.44
Randomised trial comparing the upright and supine positions for the second stage of labour. Br J Obstet Gynaecol (1997) 1.44
Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes. Am J Respir Crit Care Med (1995) 1.43
Predictors of success and failure in pulmonary rehabilitation. Eur Respir J (2006) 1.43
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest (2000) 1.43
Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet (2001) 1.42
Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol (1996) 1.42
Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol (1998) 1.40
Maternal and child health after assisted vaginal delivery: five-year follow up of a randomised controlled study comparing forceps and ventouse. BJOG (2014) 1.39
A study of the pathogenesis of experimental Salmonella dublin abortion in cattle. J Comp Pathol (1977) 1.37
Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J (1997) 1.36
Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir Med (1998) 1.33
High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord (2000) 1.32
Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis (1981) 1.32
Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis (1985) 1.30
Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology (2000) 1.30
Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis (1975) 1.28
Pathogenicity of porcine intestinal spirochetes in gnotobiotic pigs. Infect Immun (1994) 1.26
General practitioners' beliefs about their role in the prevention and treatment of accidents involving children. Br J Gen Pract (1993) 1.25
Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics (1998) 1.25
Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med (2000) 1.24
Mucociliary transport in allergic patients with antigen-induced bronchospasm. Am Rev Respir Dis (1978) 1.24
Relationship between ventilation and breathlessness during exercise in chronic obstructive airways disease is not altered by prevention of hypoxaemia. Clin Sci (Lond) (1984) 1.24
Cardiac output as a controller of ventilation through changes in right ventricular load. J Appl Physiol Respir Environ Exerc Physiol (1982) 1.23
Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ (1999) 1.22
Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil (2009) 1.21
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest (1999) 1.20
Meningitis in pigs caused by Streptococcus suis--a speculative review. Vet Microbiol (1993) 1.20
Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. Thorax (1991) 1.20
Ultrasound measured renal length versus low dose CT volume in predicting single kidney glomerular filtration rate. Br J Radiol (2004) 1.19
The role of plasmid genes in the pathogenicity of Salmonella dublin. J Med Microbiol (1986) 1.19
The reliability of the three-dimensional FASTRAK measurement system in measuring cervical spine and shoulder range of motion in healthy subjects. Rheumatology (Oxford) (2000) 1.19
The effect of temperature, solids content and pH on the survival of salmonellas in cattle slurry. Br Vet J (1976) 1.19
Minimum clinically important improvement for the incremental shuttle walking test. Thorax (2008) 1.19
Salmonella enterica serovars Typhimurium and Dublin can lyse macrophages by a mechanism distinct from apoptosis. Infect Immun (2000) 1.19
Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res (2000) 1.18
Inter-rater reliability of motor and sensory examinations performed according to American Spinal Injury Association standards. Spinal Cord (2007) 1.18